结构治疗选择的铅肥胖药物ACCG-2671,定于2025年底进行第一阶段试验。 Structure Therapeutics selects lead obesity drug ACCG-2671, set for Phase 1 trials by year-end 2025.

结构治疗学选择了ACCG-2671,一种口服小分子药物,作为治疗肥胖症的首要候选药物。 Structure Therapeutics has chosen ACCG-2671, an oral small molecule drug, as its lead candidate to treat obesity. 该药物针对Amylin和calcitonin受体,在临床前期研究中显示出有希望的结果,包括有效减重和安全剖面图。 The drug, which targets amylin and calcitonin receptors, showed promising results in preclinical studies, including effective weight loss and a safe profile. ACCG-2671预计将在2025年底前开始第一阶段临床试验。 ACCG-2671 is expected to begin Phase 1 clinical trials by the end of 2025.